When a diabetic foot ulcer refuses to heal, the problem may extend deeper than the skin. Osteomyelitis — infection of the bone — is among the most serious complications of diabetic foot disease, and it is far more common than many patients realize. Bone infection is present in roughly one in five diabetic foot ulcers overall, and in about half of wounds classified as severe infections. Its presence changes the clinical picture significantly: the risk of amputation is several times higher when bone is involved than when infection remains confined to soft tissue. Understanding how osteomyelitis is identified and managed is therefore central to protecting the diabetic foot.
Why Bone Infection Develops in the Diabetic Foot
In people with diabetes, osteomyelitis usually develops by contiguous spread — bacteria travel from a chronic skin ulcer into the underlying bone rather than arriving through the bloodstream. Several features of the diabetic foot make this progression easier. Peripheral neuropathy removes the protective sensation of pain, so wounds go unnoticed and untreated. Reduced blood flow from peripheral arterial disease limits the delivery of immune cells and antibiotics to infected tissue. And a deep or long-standing ulcer, particularly one overlying a bony prominence, offers bacteria a direct route to the skeleton. Wounds that are large, deep, or present for many weeks carry a substantially higher likelihood of underlying bone involvement.
Making the Diagnosis
Because osteomyelitis can be present even without obvious signs of infection, clinicians rely on a combination of bedside testing, imaging, and laboratory work. The 2023 IWGDF/IDSA guidelines on diabetes-related foot infections recommend a stepwise approach rather than dependence on any single test.
Clinical and bedside assessment
The probe-to-bone test — gently probing a wound with a sterile blunt instrument to feel for hard, gritty bone — remains a valuable first step. A 2023 systematic review and meta-analysis in the Journal of Clinical Medicine reported that probe-to-bone testing alone had a pooled sensitivity of approximately 0.91, and that combining it with a plain X-ray raised pooled sensitivity to about 0.94. Plain radiographs are inexpensive and widely available, although early bone changes may not become visible for two weeks or more after infection begins.
Advanced imaging and laboratory markers
When the diagnosis remains uncertain, magnetic resonance imaging (MRI) is the recommended imaging technique because of its high accuracy in detecting bone marrow changes. Inflammatory blood markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can support the diagnosis; a 2024 meta-analysis in Wound Repair and Regeneration confirmed that these biomarkers add diagnostic value, although none is definitive on its own. The reference standard remains a bone biopsy with culture and histology, which both confirms infection and identifies the responsible organisms to guide antibiotic selection.
How Osteomyelitis Is Treated
Treatment has two broad goals: eradicating the infection and preserving as much functional foot as possible. Historically, surgical removal of infected bone was considered essential in nearly every case. Current evidence shows that this is not always necessary.
The 2023 IWGDF/IDSA guidelines note that selected patients — typically those with forefoot osteomyelitis, no significant peripheral arterial disease, and no exposed bone or spreading soft-tissue infection — can be treated successfully with antibiotics alone. Across studies using bone-culture-guided therapy, roughly two-thirds of such cases reach remission without surgery. However, when there is a collection of pus, dead bone, extensive tissue destruction, or poor blood supply, prompt surgery to drain and remove infected tissue remains essential. Guidelines advise that surgical decompression of an abscess should occur within 24 hours.
How Long Should Antibiotics Continue?
The recommended duration of antibiotic therapy has shortened considerably in recent years. A 2015 multicentre randomized study in Diabetes Care found that six weeks of antibiotics was as effective as twelve weeks for nonsurgically treated osteomyelitis, with fewer drug-related side effects. A 2021 randomized pilot trial in Clinical Infectious Diseases went further: after surgical debridement, three weeks of antibiotics produced remission rates comparable to six weeks. These findings support shorter, more targeted courses, which reduce the risks of antibiotic resistance and adverse effects — though treatment length must still be individualized to the patient and the extent of infection.
Key Takeaways
Diabetic foot osteomyelitis is common, frequently silent, and strongly associated with the risk of amputation. Diagnosis is most reliable when bedside testing, imaging, and — where needed — bone biopsy are combined rather than used in isolation. Treatment is increasingly individualized: antibiotics alone can resolve many forefoot infections, surgery remains critical when there is dead bone or an abscess, and modern evidence supports shorter antibiotic courses than were once standard. Early recognition that a non-healing ulcer may signal an underlying bone infection remains the single most important factor in achieving a good outcome.
References
Senneville É, Albalawi Z, van Asten SA, et al. “IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-Related Foot Infections (IWGDF/IDSA 2023).” Clinical Infectious Diseases, 2023.
Calvo-Wright MdM, Álvaro-Afonso FJ, López-Moral M, et al. “Is the Combination of Plain X-ray and Probe-to-Bone Test Useful for Diagnosing Diabetic Foot Osteomyelitis? A Systematic Review and Meta-Analysis.” Journal of Clinical Medicine, 2023.
Ansert E, Tarricone A, Coye TL, et al. “Update of Biomarkers to Diagnose Diabetic Foot Osteomyelitis: A Meta-Analysis and Systematic Review.” Wound Repair and Regeneration, 2024.
Gariani K, Pham TT, Kressmann B, et al. “Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial.” Clinical Infectious Diseases, 2021.
Tone A, Nguyen S, Devemy F, et al. “Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study.” Diabetes Care, 2015.
Comments
